Angiex Inc.
February 11, 2025
Plymouth
Oncology
Angiex makes vascular-targeted antibody-drug conjugates for the treatment of solid cancers. Angiex's lead drug, AGX101, a TM4SF1-directed microtubule inhibitor conjugate, is currently in Phase 1 trials for all solid cancers.
Speakers
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}